Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ceftobiprole Medocaril→

Ceftobiprole Medocaril Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
376653-43-9
Molecular formula
C26H26N8O11S2
Molecular weight
690.7 g/mol
Drug class
Fifth-generation cephalosporin prodrugbroad-spectrum beta-lactam antibacterial
Mechanism of action
Ceftobiprole medocaril is converted to active ceftobiprole, which binds penicillin-binding proteins, including PBP2a in MRSA, and inhibits bacterial cell-wall synthesis.
Indications / reported uses
  • Treatment of Staphylococcus aureus bloodstream infection (bacteraemia), including right-sided infective endocarditis, caused by methicillin-susceptible or methicillin-resistant isolates in adults
  • Treatment of acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia in eligible patients under the product-specific label; route and age eligibility vary by indication
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Ceftobiprole Medocaril Environmental Risk Assessment (ERA) (the Ceftobiprole Medocaril ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.